Bristol Myers Squibb (BMY) on Tuesday announced a collaboration with Microsoft (MSFT) to speed up early detection of lung cancer using the tech giant’s artificial intelligence-powered radiology technology platform.
As part of the deal, the FDA-cleared radiology AI algorithms will be implemented through Microsoft’s (MSFT) Precision Imaging Network, which is widely adopted by various U.S. healthcare providers.
MSFT’s Precision Imaging Network leverages AI capabilities to detect lung diseases through X-ray and CT images.
One of the key objectives of the partnership is to widen access to early detection across rural hospitals, community clinics, and other medically underserved communities in the U.S., the companies said.
“This is a clear win for both patients and providers and aligns with Microsoft’s goals to utilize technology to unlock insights, increase efficiencies, and improve patient care,” added Bristol Myers’ Chief Strategy Officer, Peter Durlach.